Year: 2023

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services has named Ian Freeman as its new Chief Commercial Officer of Virtuals effective November 16, 2023. His responsibilities will include the innovation, delivery, and growth of Inspired’s Virtual Sports products. Ian is a seasoned industry veteran with more than two decades of experience in sports and iGaming. He has held key leadership positions in global gaming and technology, working with top companies in the industry. Most recently, Ian served as Chief Revenue Officer for FSBTech, a leading sports and iGaming platform provider. He focused on driving customer acquisition and retention, revenue growth, and global market expansion, including...

WILMINGTON, Del., Oct. 17, 2023 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile and video technology research and development company, today announced that the company will release its third quarter 2023 financial results before market open on Thursday, November 2, 2023. InterDigital executives will host a conference call that same day at 10:00 a.m. Eastern Time (ET) to discuss the company’s performance. For a live Internet webcast of the conference call, visit www.interdigital.com and click on the “Webcast” link on the Investors page. The company encourages participants to take advantage of the Internet option. For telephone access to the conference call, visit www.interdigital.com and click on the “Dial In Registration” link on the Investors page. Registration is necessary to obtain a dial in phone number...

Combining FlexNoC and Ncore from Arteris with Fraunhofer IESE DRAMSys4.0 enables customers to improve performance, reduce cost and accelerate the advanced DRAM-centric SoC development schedules CAMPBELL, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation and Fraunhofer IESE, one of the leading research institutes in the area of software and systems engineering methods, today announced they have partnered to enable interoperability between Arteris’ FlexNoC and Ncore network-on-chip (NoC) development environment and Fraunhofer IESE’s DRAM subsystem design space exploration framework. The interoperability will improve performance, reduce cost and accelerate the schedule of advanced DRAM-centric NoC development for mutual...

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) Initial Combination Therapy Clinical Data Anticipated in Q2 2024 SEATTLE, Oct. 17, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the first patient has been dosed in Part B of its Phase 1/2 VISTA-101 clinical trial that will evaluate the safety and tolerability of the company’s VISTA blocking immunotherapy, KVA12123, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. “Dosing the first patient in the combination arm with...

Wood Dale, Illinois, Oct. 17, 2023 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, has signed a multi-year contract extension with MTU Maintenance, the global market leader in customized solutions for aero engines, to supply parts for Pratt & Whitney PW2000 engines. This fourth extension marks the continuation of an AAR-MTU contract that originally began in 2009. Under the agreement, AAR supplies used serviceable material for the PW2000 engine program at MTU’s facility in Hannover, Germany. This partnership significantly streamlines logistical processes and creates cost efficiencies for MTU Maintenance’s customers. “The last 15 years have shown us that AAR is a reliable partner, which helps us to offer tailor-made and cost-efficient...

Powered by Acxiom, Real ID Accelerates Growth for Brands With 360-Degree View of Customers New York, NY, Oct. 17, 2023 (GLOBE NEWSWIRE) — Interpublic Group (NYSE: IPG) today unveiled Real IDä in the Cloud, an identity resolution application built by Acxiom and designed to seamlessly integrate with a brand’s secure cloud ecosystem to power growth in a cookie-less world. Real ID enables marketers to recognize the real people behind the scattered data points, swiftly creating accurate, holistic customer views that tap into Acxiom’s best-in-class data assets. Real ID accelerates growth for brands by enhancing a marketer’s existing first-party data, without the cost, complexity, and risk of moving personally identifiable information (PII). “At a time when personalized brand experiences are what every brand and marketer need to...

Actelis Solution is selected to rapidly modernize and digitize operations FREMONT, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ:ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT applications, today announced that it has received a first order to supply a major European natural gas transmission system operator with its hybrid fiber-copper networking solution as part of a new tender win. This new win demonstrates Actelis’ continued growth within critical IoT networks around the world. Actelis’ new customer operates a high-pressure natural gas pipeline network stretching over thousands of kilometers in a large European country. The company operates in an industry that is heavily regulated and requires strict monitoring of all operational...

Example of a cranial implantExample of a cranial implant produced using VESTAKEEP® i4 3DF PEEK by Evonik on 3D Systems’ EXT 220 MED extrusion platform.Patient-specific cranial implant produced with 3D Systems’ point-of-care additive manufacturing technologies used in pioneering surgery at University Hospital Basel (Switzerland) 3D Systems’ technologies enabled first 3D-printed cranial implant used in surgery at Salzburg University Hospital (Austria) Company’s additive manufacturing technologies enabling advances in cranial implants market — anticipated to reach more than $2 billion by 2030ROCK HILL, S.D., Oct. 17, 2023 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE:DDD) announced a patient-specific 3D-printed cranial implant produced using its point-of-care technologies was successfully used in a cranioplasty at the University...

15% Net Revenue and 109% Gross Profit Increases for the First-Half 2023 Compared to the First-Half 2022 Rimawari-kun Members Reached 261,633 as of June 30, 2023, a 58% Increase from a Year Ago and a 10％ Increase from FY2022 Year-End SYLA Continues to Aim for Fiscal Prudence and Health; Strives for an Equity Ratio of 30% while Targeting a 10% Return on Sales and a Payout Ratio of 30% TOKYO, Oct. 17, 2023 (GLOBE NEWSWIRE) — SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowd-funding platform in Japan, Rimawari-kun, reported its interim financial results for the six months ended June 30, 2023. First Half 2023 Recent Operational Highlights:As of June 30, 2023, the number of Rimawari-kun members reached 261,633, and gross merchandise volume (total amount raised...

FREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment. The study entitled “A Phase IIb Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients with Adult Attention-Deficit/Hyperactivity Disorder” is a randomized, double-blind, placebo-controlled study involving a total of approximately 100 patients...